NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT06934044 2026-03-16
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1 Recruiting
NCT05533775 2026-03-06
iMATRIX GLO
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05583617 2026-03-06
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT03075696 2026-03-05
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05927571 2026-03-05
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Recruiting
NCT06624085 2026-03-04
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting
NCT05091424 2026-03-03
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 1 Recruiting
NCT06084936 2026-03-03
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT04524871 2026-02-27
MORPHEUS-LIVER
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05169515 2026-02-23
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1 Recruiting
NCT03564340 2025-12-03
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT04291755 2024-04-05
Development and Analysis of a Stool Bank for Cancer Patients
Persephone Biosciences
Recruiting